NEPHROS INC

Form 4

November 16, 2007

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB Number:

3235-0287

2005

0.5

January 31, Expires:

OMB APPROVAL

Estimated average

burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person * Lambda Investors LLC

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

Symbol

(First)

NEPHROS INC [NEP]

(Check all applicable)

411 WEST PUTNAM

3. Date of Earliest Transaction (Month/Day/Year)

Director Officer (give title below)

10% Owner Other (specify

AVENUE. SUITE 125

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line)

Filed(Month/Day/Year)

11/14/2007

X Form filed by One Reporting Person Form filed by More than One Reporting

GREENWICH, CT 06830

(City) (State) (Zip)

(Street)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed (Month/Day/Year)

Execution Date, if (Month/Day/Year)

(Middle)

3. 4. Securities Acquired (A) or TransactiorDisposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)

5. Amount of Securities Beneficially Form: Owned Following Reported (I)

7. Nature of Ownership Indirect Beneficial Direct (D) Ownership or Indirect (Instr. 4)

(A) or Code V (D) Amount

Transaction(s)

(Instr. 4) (Instr. 3 and 4)

D

Common Stock

11/14/2007

 $\mathbf{C}^{(1)}$ 14,381,621

14,381,621 0.706

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Price

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: NEPHROS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of on Securities According Disposed of (Unstr. 3, 4, and	quired (A) or D)	nired (A) or Expiration Date (Month/Day/Y		7. Titl Under (Instr.
	Security			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
Series A 10% Secured Convertible Note due 2008	\$ 0.706	11/14/2007		C(1)	. ,	\$ 10,153,424 (1)	<u>(2)</u>	(3)	Com Stock a Wa to Purc Com St
Class D Warrant for the Purchase of Shares of Common Stock	\$ 0.9	11/14/2007		C(1)	7,190,811		11/14/2007	11/14/2012	Com Sto

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Lambda Investors LLC 411 WEST PUTNAM AVENUE SUITE 125 GREENWICH, CT 06830		X				

Signatures

Arthur Amron, Vice President and Assistant 11/16/2007 Secretary

> **Signature of Reporting Person Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These transactions reflect the conversion of a Series A 10% Secured Convertible Note due 2008 in the original principal amount of \$10,000,000 (the ?Note?) into 14,381,621 shares of common stock and a Class D Warrant to purchase 7,190,811 shares of common stock

- (1) (the ?Warrant?). The amount due under the Note at the time of conversion, including interest that accrued between the issuance and conversion of the Note, was \$10,153,424.66. The Note was converted into common stock at a conversion price of \$0.706 per share, and the number of shares underlying the Warrant is equal to 50% of the number of shares of common stock issued upon conversion.
- The Note would only convert on the twenty-first (21st) day after the issuer sent or gave its stockholders a definitive Schedule 14C information statement relating to certain actions taken by stockholders of the issuer by written consent.
- (3) The maturity date of the Note prior to its conversion was September 19, 2008.

Reporting Owners 2

Edgar Filing: NEPHROS INC - Form 4

Based on the original principal amount of the Note, the Note would have been convertible into 14,164,306 shares of common stock and a warrant to purchase an additional 7,082,153 shares of Common Stock (for a total of 21,246,459 underlying shares of common stock). As a result of the accrual of interest, the Note was actually converted into 14,381,621 shares of common stock and the Warrant to purchase an additional 7,190,811 shares of common stock (for a total of 21,572,432 underlying shares of common stock).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.